We present herein two unusual cases of multicentric liposarcoma which highlight the problems associated with the management of this disease entity. When the surgeon is confronted with multicentric liposarcomas, it is necessary to define whether they are secondary tumors or independently arising multicentric liposarcomas, since the latter situation merits a more aggressive approach. Guidelines for this differentiation are suggested in the discussion following the case reports. Surgery, which is often multiple, remains the mainstay of treatment, although adjuvant chemotherapy and radiotherapy are also usually required.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/BF00311825 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Diaphragmatic Castleman's disease: A rare lymphoproliferative disorder: Clinical and radiological perspectives.
Radiol Case Rep
December 2024
Radiology, University of Miami Miller School of Medicine, Miami, FL, USA.
Article Synopsis
- - Castleman's disease (CD) is a rare and benign disorder of the lymphatic system, which can be challenging to diagnose due to its vague symptoms and unclear cause.
- - CD comes in two main types: unicentric (UCD) and multicentric (MCD), with MCD further split into forms linked to HHV-8 virus and idiopathic causes; symptoms include fever, weight loss, and organ enlargement.
- - Diagnosing CD relies on specific histopathological criteria and imaging techniques like CT, MRI, and PET-CT, with a case study demonstrating the importance of thorough imaging and clinical assessment for effective management.
TRAbectedin in adVanced rEtroperitoneal well differentiated/dedifferentiated Liposarcoma and Leiomyosarcoma (TRAVELL): results of a phase II study from the Italian Sarcoma Group.
ESMO Open
August 2024
Fondazione IRCC Istituto Nazionale Tumori, Medical Oncology 2, Milan.
Background: This is a multicentre, single-arm, phase II study aimed at further exploring the activity of trabectedin as second-/further-line treatment in retroperitoneal leiomyosarcoma (LMS) and well-differentiated/dedifferentiated liposarcoma (LPS).
Materials And Methods: The primary endpoint was the growth modulation index (GMI) defined as the ratio between PFS under trabectedin (PFS) and during previous chemotherapy treatment: time to progression (TTP-1). Secondary endpoints were objective response rate (ORR) and PFS.
Soft tissue tumor imaging in adults: whole-body staging in sarcoma, non-malignant entities requiring special algorithms, pitfalls and special imaging aspects. Guidelines 2024 from the European Society of Musculoskeletal Radiology (ESSR).
Eur Radiol
January 2025
Department of Radiology, Leiden University Medical Center, Leiden, The Netherlands.
Objectives: The revised European Society of Musculoskeletal Radiology (ESSR) consensus guidelines on soft tissue tumor imaging represent an update of 2015 after technical advancements, further insights into specific entities, and revised World Health Organization (2020) and AJCC (2017) classifications. This second of three papers covers algorithms once histology is confirmed: (1) standardized whole-body staging, (2) special algorithms for non-malignant entities, and (3) multiplicity, genetic tumor syndromes, and pitfalls.
Materials And Methods: A validated Delphi method based on peer-reviewed literature was used to derive consensus among a panel of 46 specialized musculoskeletal radiologists from 12 European countries.
Multiple Recurrent Atypical Lipomatous Tumors/Well-Differentiated Liposarcomas and Dedifferentiated Liposarcomas Treated with Multiple Surgical Resections: A Case Report.
Case Rep Oncol
October 2023
Department of Orthopaedic Surgery, Keio University School of Medicine, Tokyo, Japan.
Article Synopsis
- * The patient had severe mobility issues due to large tumors throughout his body, necessitating multiple surgeries which ultimately improved his ability to perform daily activities.
- * Although he eventually developed an unresectable dedifferentiated liposarcoma that led to his death at 79, this case highlights that surgical intervention can significantly benefit patients even with multiple large tumors.
Anlotinib as a maintenance treatment for advanced soft tissue sarcoma after first-line chemotherapy (ALTER-S006): a multicentre, open-label, single-arm, phase 2 trial.
EClinicalMedicine
October 2023
Melanoma and Sarcoma Medical Oncology Unit, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.
Background: No standard maintenance treatment has been obtained to prolong the response duration of soft tissue sarcoma (STS) after first-line chemotherapy. In this study, we aimed to evaluate the efficacy and safety of anlotinib as a maintenance treatment after chemotherapy in STS.
Methods: In this multicentre, open-label, single-arm phase 2 trial, patients with advanced STS who achieved partial response or stable disease after first-line anthracycline-based chemotherapy were enrolled between April 2019 and January 2022.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!